Holen Sie sich die Stockscreener-App
438.66
1.52%
-6.77
Handel nachbörslich:
438.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$445.43
Offen:
$441.39
24-Stunden-Volumen:
563.19K
Relative Volume:
0.72
Marktkapitalisierung:
$19.79B
Einnahmen:
$3.08B
Nettoeinkommen (Verlust:
$1.24B
KGV:
17.13
EPS:
25.6108
Netto-Cashflow:
$1.07B
1W Leistung:
+4.18%
1M Leistung:
-3.18%
6M Leistung:
+48.90%
1J Leistung:
+17.28%
1-Tages-Spanne:
$432.00
$446.00
1-Wochen-Bereich:
$409.07
$479.50
52-Wochen-Spanne:
$266.98
$479.50
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease - The Joplin Globe
United Therapeutics (Nasdaq: UTHR) starts EXPAND with first UKidney xenotransplant - Stock Titan
Can technical indicators confirm United Therapeutics Corporation’s reversalWeekly Stock Report & High Accuracy Swing Trade Signals - newser.com
United Therapeutics Hits Day High with 9.63% Surge in Stock Price - Markets Mojo
Is United Therapeutics Corporation (UTH) stock a top dividend aristocrat candidateRisk Management & Reliable Entry Point Trade Alerts - newser.com
MSN Money - MSN
United Therapeutics Corp. Hits New 52-Week High of $479.50 - Markets Mojo
United Therapeutics posts record revenue but misses Q3 earnings expectations - MSN
Focus Partners Advisor Solutions LLC Buys Shares of 1,440 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation - MSN
United Therapeutics CEO Martine A. Rothblatt Sells 8,000 Shares - TradingView
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup - Law360
United Therapeutics (NASDAQ:UTHR) Given New $423.00 Price Target at Wells Fargo & Company - MarketBeat
Assetmark Inc. Boosts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics Corporation stock benefit from upcoming earnings reportsOptions Play & Technical Pattern Alert System - newser.com
United Therapeutics Executives Sell Shares - TradingView
United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation - Nasdaq
United Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
United Therapeutics price target raised to $587 from $569 at RBC Capital - TipRanks
United Therapeutics price target raised to $447 from $435 at Morgan Stanley - TipRanks
United Therapeutics (UTHR) Earnings Transcript - AOL.com
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics’ AI-Driven Study: A Potential Game-Changer for Pulmonary Hypertension Diagnosis - MSN
United Therapeutics’ PHINDER Study: A Step Forward in Early Detection of Pulmonary Hypertension - MSN
Silver Spring-based United Therapeutics reports Q3 earnings - Maryland Daily Record
Published on: 2025-10-31 23:58:52 - newser.com
United Therapeutics Reports Record Q3 2025 Results - TipRanks
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics: Q3 Earnings Snapshot - CT Insider
United Therapeutics (NASDAQ:UTHR) COO Sells $9,393,750.00 in Stock - MarketBeat
Why Is United Therapeutics (UTHR) Stock Soaring Today - Yahoo Finance
United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark - TradingView
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
United Therapeutics Q3 2025 Earnings ReportRevenue & Profit AnalysisNews and Statistics - IndexBox
United Therapeutics Q3 2025 Earnings: Profit Beats ForecastsNews and Statistics - IndexBox
United Therapeutics (UTHR) Beats Q3 Earnings Estimates - Yahoo Finance
United Therapeutics Grows Revenue, But Misses Earnings Forecast - Finimize
United Therapeutics Corp Q3 2025 Earnings: EPS of $7.16 Beats Es - GuruFocus
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings - Yahoo Finance
United Therapeutics Corp Announces Rise In Q3 Bottom Line - Nasdaq
United Therapeutics misses Q3 expectations despite record revenue - Investing.com
United Therapeutics misses Q3 expectations despite record revenue By Investing.com - Investing.com Philippines
United Therapeutics Q3 revenue misses estimates - TradingView
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
Sumitomo Mitsui Trust Group Inc. Has $28.81 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Shares Acquired by Y Intercept Hong Kong Ltd - MarketBeat
United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Will United Therapeutics Corporation stock outperform value stocksTrade Performance Summary & Community Verified Swing Trade Signals - fcp.pa.gov.br
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):